Neoadjuvant Treatment of Prostate Cancer With Bicalutamide and Raloxifene Prior to Radical Prostatectomy
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2019
Price : $35 *
At a glance
- Drugs Bicalutamide (Primary) ; Raloxifene (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 17 Jan 2019 Status changed from recruiting to withdrawn prior to enrolment.
- 31 Aug 2018 Biomarkers information updated
- 27 Jun 2017 Status changed from not yet recruiting to recruiting.